This website contains information intended only for persons professionally dealing with medical devices (e.g. for persons performing medical professions, for persons dealing with the distribution of medical devices). Please confirm that you are a medical device professional to proceed.
Cardiolens FFR-CT Pro® Diagnostic TestAt Hemolens Diagnostics, we have developed a non-invasive method of diagnosing coronary artery disease with the help of FFR-CT. Cardiolens FFR-CT Pro® combines two non-invasive diagnostic tools: Coronary Computed Tomography Angiography (CCTA) and Continuous Non-invasive Blood Pressure (CNBP). In combination with computational fluid dynamic principles, these data are used to generate a 3D model of the blood vessels, allowing for a detailed anatomical and functional evaluation of coronary arteries. This information allows the overseeing physician to better evaluate stenosis severity and thereby plan appropriate treatment or follow-up.
Hemolens Diagnostics follows the unstoppable trend of the digitalization of medicine. Drawing from computational fluid dynamics algorithms, this technology can be applied in the future to numerous other disciplines including oncology, pulmonology, angiology or neurology. It could soon become the gold standard around the globe.
The FFR-CT measurement and 3D coronary models are obtained using computational fluid dynamics algorithms. Coronary CT angiography (CCTA) and continuous non-invasive blood pressure (CNBP) measurements from each patient are used as the basis input for these algorithms to generate accurate patient specific simulations of their coronary artery network.
The physician receives the test results in the form of a 3D image of the coronary vasculature, with anatomically significant stenoses flagged. Pointing to a given stenosis displays the relevant calculated FFR-CT parameter.
I believe that together with Hemolens Diagnostics we will create a new standard that will enable non-invasive FFR-CT diagnostics in patients with intermediate-risk coronary artery disease. This is for those who, due to contraindications, would not get this diagnosis by invasive means.
Hemolens Diagnostics, using FFR-CT, offers and is developing a novel and promising technology for the detection of anatomically and functionally significant coronary artery stenosis based on non-invasive testing: coronary computed tomography angiography (CCTA) and continuous non-invasive blood pressure (CNBP). Methods based on determination of the fractional flow reserve (FFR) from computed tomography of the coronary arteries are recommended by international scientific societies.
I became involved in the Hemolens Diagnostics collaboration because I believe that with advanced technology, we can push the boundaries of current diagnostic procedures and provide increasingly precise information for clinical practice. Non- invasive testing is the foundation of the medicine of the future.
